Regulatory and Washington

  • Cannabis industry hails DEA's clarification on CBD
    The Drug Enforcement Administration has further clarified its stance on the legality of cannabidiol and confirmed that some CBD products are legal to distribute freely throughout the United States and do not fall under the regulations of the Controlled Substances Act, a move that has drawn praise from CBD retailers.

  • E-prescribing bill clears Senate panel
    The Senate Finance Committee has passed the Every Prescription Conveyed Securely Act, little more than a month after the House Energy and Commerce Committee passed its House counterpart.

  • Survey: Youth tobacco use flattens in 2017
    As new and novel tobacco products that appeal to youth continue to hit the market, research shows that tobacco use rates among middle and high school students essentially flattened in 2017 after an encouraging decline from 2015 to 2016, according to the National Youth Tobacco Survey results, released Thursday by the Centers for Disease Control and Prevention.

  • CHPA submits statement for hearing on benefits of consumer-directed health plans
    The Consumer Healthcare Products Association, a national trade association representing manufacturers and marketers of OTC medicines and dietary supplements, applauded the U.S. House Ways and Means Health Subcommittee for Wednesday’s hearing on the benefits of consumer-directed health plans and submitted a statement reiterating its support of legislation to restore OTC eligibility under tax-preferred healthcare accounts.

  • FDA seeks injunction against company selling unapproved hand sanitizers
    The U.S. Food and Drug Administration on Wednesday filed a complaint against Innovative BioDefense of Lake Forest, Calif., and Colette Cozean, the company's president and CEO, to prohibit them from selling Zylast topical antiseptics with claims that they are effective against infection by pathogens such as norovirus, rotavirus, flu virus, Methicillin-Resistant Staphylococcus Aureus (MRSA), and Ebola.

  • New Hampshire adopts retail tech to prevent illegal sales of pseudoephedrine
    New Hampshire has adopted the real-time, stop-sale National Precursor Log Exchange technology, becoming the 35th state to adopt the system used by retailers across the country to help prevent the illegal sale of pseudoephedrine.

  • FDA warns companies to stop selling highly concentrated caffeine products
    The U.S. Food and Drug Administration announced on Tuesday that it has issued warning letters to the parties responsible for liquidcaffeine.com and Dual Health Body and Mind for illegally selling certain highly concentrated caffeine products. The FDA considers these products to be a threat to public health.

  • Amgen’s Herceptin biosimilar rejected by FDA
    The Food and Drug Administration sent Amgen a complete response letter for its Biologics License application for potential Herceptin biosimilar ABP 90.
X
This ad will auto-close in 10 seconds